J B Chemicals and Pharmaceuticals has received a buy rating from Prabhudas Lilladher with a target price of ₹2,300 per share, following the company's strong Q3FY26 performance and positive growth outlook.

Q3FY26 Financial Performance

The company delivered robust financial results in Q3FY26, with key metrics aligning with analyst expectations:

Growth Drivers and Strategic Initiatives

Prabhudas Lilladher expects JB Chemicals' growth momentum to continue, supported by multiple strategic drivers:

• Geographical expansion of legacy brands into new markets
• Improvement in medical representative productivity through enhanced sales strategies
• Scale up of acquired brands to maximize portfolio value
• Launch of new products and therapies to diversify revenue streams
• Scaling up contract manufacturing business for additional revenue growth
• Strong free cash flow generation supporting business expansion

Corporate Developments and Timeline

The management has provided clarity on key corporate transactions and expected timelines:

Financial Projections and Valuation

The brokerage has made minor adjustments to its earnings projections while maintaining a positive outlook:

Margin Improvement Outlook

The research firm anticipates significant margin expansion beyond FY27E, driven by the grant of perpetual license for the acquired ophthalmic portfolio. This development is expected to enhance the company's profitability profile and strengthen its competitive position in the pharmaceutical sector.

Prabhudas Lilladher maintains its buy recommendation, citing the company's strong fundamentals, diversified growth strategy, and attractive valuation at current market price relative to the target price of ₹2,300 per share.

J.B. Chemicals & Pharmaceuticals Limited has announced the availability of its Q3FY26 earnings call recording, providing investors and analysts with access to management discussions on the company's third quarter performance and developments.

Earnings Call Disclosure

The company has made the audio recording of its conference call available on its official website, following the investor and analyst session held on January 19, 2026 at 1:30 PM IST. The call focused on results and developments for the third quarter ended December 31, 2025.

Regulatory Compliance

The disclosure has been made pursuant to Regulation 30 read with Schedule III and Regulation 46(2)(oa) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulatory framework mandates companies to make such investor communications publicly accessible.

Previous Performance Context

The company had previously demonstrated resilient performance with sustained sales momentum despite challenging year-over-year comparisons. Management had expressed optimism about maintaining positive sales momentum, indicating confidence in the company's operational performance and market positioning in the pharmaceutical sector.

Access Information

Investors and analysts can access the Q3FY26 earnings call recording through the dedicated link provided on the company's website. The communication was formally disclosed to BSE Limited under the company's scrip code 506943 and stock symbol JBCHEPHARM, ensuring transparency and regulatory compliance for all stakeholders.